Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: Clinical outcomes with the 'CROSS-regimen' in daily practice

Marissa Cloos-V.balen, Edmée S.H. Portier, Marta Fiocco, Henk H. Hartgrink, Alexandra M.J. Langers, Karen J. Neelis, Irene M. Lips, Femke P. Peters, Marije Slingerland

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background and objectives: Since the first results of the Dutch randomized CROSS-trial, neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel followed by resection for primary resectable nonmetastatic esophageal cancer (EC) has been implemented as standard curative treatment in the Netherlands. The purpose of this retrospective study is to evaluate the clinical outcomes of this treatment in daily practice in a large academic hospital. Methods: Medical records of patients treated for primary resectable nonmetastatic EC between May 2010 and December 2015 at our institution were reviewed. Treatment consisted of five weekly courses of carboplatin (area under the curve 2) and paclitaxel (50 mg/m2) with concurrent external beam radiotherapy (23 fractions of 1.8 Gy), followed by transthoracic or transhiatal resection. Data on survival, progression, acute and late toxicity were recorded. Results: A total of 145 patients were included. Median follow-up was 43 months. Median overall survival (OS) and progression-free survival (PFS) were 35 (95% confidence interval [CI] 29.8-40.2) and 30 (95% CI 19.7-40.3) months, respectively, with corresponding 3-year OS and PFS of 49.6% (95% CI 40.4-58.8) and 45.6% (95% CI 36.6-54.6). Acute toxicity grade ≥3 was observed in 25.5% of patients. Late adverse events grade ≥3 were seen in 24.8%, mostly esophageal stenosis. Conclusion: Neoadjuvant CRT followed by resection for primary resectable nonmetastatic EC in daily practice results in a 3-year OS of 49.6% (95% CI 40.4-58.8) and PFS of 45.6% (95% CI 36.6-54.6), compared with 58% (51-65%) and 51% (43-58%) within the CROSS-trial. The slightly poorer survival in our daily practice group might be due to the presence of less favorable patient and tumor characteristics in daily practice, as is to be expected in daily practice. Toxicity was comparable with that in the CROSS-trial and considered acceptable.

Original languageEnglish
Article numberdoab068
JournalDiseases of the Esophagus
Issue number4
Publication statusPublished - 19 Apr 2022
Externally publishedYes


  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Carboplatin
  • Chemoradiotherapy
  • Esophageal Neoplasms/pathology
  • Humans
  • Neoadjuvant Therapy/methods
  • Paclitaxel
  • Retrospective Studies


Dive into the research topics of 'Neoadjuvant chemoradiotherapy followed by resection for esophageal cancer: Clinical outcomes with the 'CROSS-regimen' in daily practice'. Together they form a unique fingerprint.

Cite this